Drug intelligence / Profile preview

NVP-1703

Development stage: Unknown
Lead developer: NVP Healthcare
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**NVP-1703** is an orally administered probiotic mixture comprising *Bifidobacterium longum* IM55 and *Lactobacillus plantarum* IM76, developed by NVP Healthcare for allergic rhinitis. The product is intended to modulate allergic immune responses, with clinical and preclinical findings showing increased interleukin-10 expression and attenuation of type 2 inflammatory signaling including interleukin-4, accompanied by reductions in allergen-specific IgE and nasal symptom burden. It has been recognized by the Korean Ministry of Food and Drug Safety as a health functional food ingredient rather than a conventional pharmaceutical medicine.

Targets

IL10 (Interleukin-10)IL-4 (Interleukin 4)

Beyond the preview

Go deeper on NVP-1703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-1703.

Explore the full profile